Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Inhibikase Therapeutics (IKT) reported financial results for Q4 and the full year 2020, noting a net loss of $1.21 million in Q4, improving from $0.43 million in Q4 2019. For the full year, the net loss was $2.85 million, down from $5.72 million in 2019. The company completed its IPO in December 2020, raising approximately $14.60 million. In early 2021, it commenced patient dosing for IkT-148009, aimed at treating Parkinson's disease, and initiated chronic toxicology studies. Cash reserves stood at $13.95 million as of year-end 2020, supporting ongoing research initiatives.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference on March 9, 2021. This online presentation can be accessed in the Investors section of their website starting at 7:00 am ET. The webcast will be available for approximately 90 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease, with its lead program IkT-148009 currently in Phase I trials assessing its safety and pharmacokinetics.
Inhibikase Therapeutics (Nasdaq: IKT) announced it will present findings on its oral therapy IkT-148009 for Parkinson's disease at the virtual ASENT 2021 Annual Meeting from February 22-25, 2021. CEO Milton Werner, Ph.D., will showcase the therapeutic effects observed in humanized mouse models, emphasizing the role of alpha-synuclein plaques in disease progression. The presentation is scheduled for February 25, 2021, at 10:20 AM ET, followed by a panel discussion. IkT-148009, currently in Phase 1 trials, aims to modify Parkinson's disease progression.
Inhibikase Therapeutics (Nasdaq: IKT) has initiated dosing in a Phase 1 clinical trial for IkT-148009, a c-Abl inhibitor targeting Parkinson’s disease. This study focuses on the safety and pharmacokinetics of IkT-148009 in healthy volunteers aged 45-70. The drug has shown promise in preclinical studies for halting and reversing functional loss in Parkinson's. CEO Milton Werner expressed that this milestone could lead to a transformative therapy for millions. Parkinson’s affects approximately 1 million people in the U.S., highlighting the significance of Inhibikase’s research.
Inhibikase Therapeutics (Nasdaq: IKT) has partnered with Clintrex Research Corporation to enhance its clinical development for Parkinson's disease and related disorders. Clintrex will manage clinical trials and regulatory aspects for Inhibikase's drug candidates, including IkT-148009 and IkT-001Pro. Dr. C. Warren Olanow, CEO of Clintrex, will take on the role of Interim Chief Medical Officer for Inhibikase. This collaboration aims to expedite the clinical advancement of treatments targeting serious neurological conditions.
Inhibikase Therapeutics, a clinical-stage pharmaceutical company, has successfully closed its initial public offering, selling 1,800,000 shares at $10.00 each, generating $18 million in gross proceeds. Additionally, underwriters have a 45-day option to purchase up to 270,000 additional shares. The company's stock began trading on the Nasdaq Capital Market under the ticker symbol 'IKT' on December 23, 2020. ThinkEquity is the sole book-running manager for this offering.
Inhibikase Therapeutics has priced its initial public offering (IPO) at $10.00 per share, offering 1,800,000 shares and raising $18 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under the ticker symbol IKT starting December 23, 2020, with the offering expected to close on December 28, 2020. The underwriters also have a 45-day option for an additional 270,000 shares. ThinkEquity serves as the sole book-running manager for the offering.